Cargando…
Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic argin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135817/ https://www.ncbi.nlm.nih.gov/pubmed/27912793 http://dx.doi.org/10.1186/s13075-016-1192-x |
_version_ | 1782471614615519232 |
---|---|
author | Ziegelasch, Michael van Delft, Myrthe A. M. Wallin, Philip Skogh, Thomas Magro-Checa, César Steup-Beekman, Gerda M. Trouw, Leendert A. Kastbom, Alf Sjöwall, Christopher |
author_facet | Ziegelasch, Michael van Delft, Myrthe A. M. Wallin, Philip Skogh, Thomas Magro-Checa, César Steup-Beekman, Gerda M. Trouw, Leendert A. Kastbom, Alf Sjöwall, Christopher |
author_sort | Ziegelasch, Michael |
collection | PubMed |
description | BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic arginine peptide (CAP) is typically present. Antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor (RF)-negative cases long before clinical onset of RA. We analysed these antibody specificities in sera from European patients with SLE in relation to phenotypes, smoking habits and imaging data. METHODS: Cases of SLE (n = 441) from Linköping, Sweden, and Leiden, the Netherlands, were classified according to American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria. IgG anti-CCP, anti-CAP and anti-CarP were analysed by immunoassays. Radiographic data from 102 Swedish patients were available. RESULTS: There were 16 Linköping (6.8%) and 11 Leiden patients (5.4%) who were anti-CCP-positive, of whom approximately one third were citrulline-dependent: 40/441 (9.1%) were anti-CarP-positive, and 33% of the anti-CarP-positive patients were identified as anti-CCP-positive. No associations were found comparing anti-CCP or anti-CarP with ACR-defined phenotypes, immunologic abnormalities or smoking habits. Radiographically confirmed erosions were found in 10 patients, and were significantly associated with anti-CCP, anti-CarP and RF. Musculoskeletal ultrasonography scores were higher in anti-CCP-positive compared to anti-CCP-negative patients. CONCLUSIONS: In the hitherto largest anti-CarP study in SLE, we demonstrate that anti-CarP is more prevalent than anti-CCP and that the overlap is limited. We obtained some evidence that both autoantibodies seem to be associated with erosivity. Similar pathogenetic mechanisms to those seen in RA may be relevant in a subgroup of SLE cases with a phenotype dominated by arthritis. |
format | Online Article Text |
id | pubmed-5135817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51358172016-12-15 Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts Ziegelasch, Michael van Delft, Myrthe A. M. Wallin, Philip Skogh, Thomas Magro-Checa, César Steup-Beekman, Gerda M. Trouw, Leendert A. Kastbom, Alf Sjöwall, Christopher Arthritis Res Ther Research Article BACKGROUND: Articular manifestations are common in systemic lupus erythematosus (SLE) whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are citrulline-dependent in rheumatoid arthritis (RA), whereas the opposite is suggested in SLE, as reactivity with cyclic arginine peptide (CAP) is typically present. Antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor (RF)-negative cases long before clinical onset of RA. We analysed these antibody specificities in sera from European patients with SLE in relation to phenotypes, smoking habits and imaging data. METHODS: Cases of SLE (n = 441) from Linköping, Sweden, and Leiden, the Netherlands, were classified according to American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria. IgG anti-CCP, anti-CAP and anti-CarP were analysed by immunoassays. Radiographic data from 102 Swedish patients were available. RESULTS: There were 16 Linköping (6.8%) and 11 Leiden patients (5.4%) who were anti-CCP-positive, of whom approximately one third were citrulline-dependent: 40/441 (9.1%) were anti-CarP-positive, and 33% of the anti-CarP-positive patients were identified as anti-CCP-positive. No associations were found comparing anti-CCP or anti-CarP with ACR-defined phenotypes, immunologic abnormalities or smoking habits. Radiographically confirmed erosions were found in 10 patients, and were significantly associated with anti-CCP, anti-CarP and RF. Musculoskeletal ultrasonography scores were higher in anti-CCP-positive compared to anti-CCP-negative patients. CONCLUSIONS: In the hitherto largest anti-CarP study in SLE, we demonstrate that anti-CarP is more prevalent than anti-CCP and that the overlap is limited. We obtained some evidence that both autoantibodies seem to be associated with erosivity. Similar pathogenetic mechanisms to those seen in RA may be relevant in a subgroup of SLE cases with a phenotype dominated by arthritis. BioMed Central 2016-12-03 2016 /pmc/articles/PMC5135817/ /pubmed/27912793 http://dx.doi.org/10.1186/s13075-016-1192-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ziegelasch, Michael van Delft, Myrthe A. M. Wallin, Philip Skogh, Thomas Magro-Checa, César Steup-Beekman, Gerda M. Trouw, Leendert A. Kastbom, Alf Sjöwall, Christopher Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title | Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title_full | Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title_fullStr | Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title_full_unstemmed | Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title_short | Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts |
title_sort | antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined european cohorts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135817/ https://www.ncbi.nlm.nih.gov/pubmed/27912793 http://dx.doi.org/10.1186/s13075-016-1192-x |
work_keys_str_mv | AT ziegelaschmichael antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT vandelftmyrtheam antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT wallinphilip antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT skoghthomas antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT magrochecacesar antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT steupbeekmangerdam antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT trouwleenderta antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT kastbomalf antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts AT sjowallchristopher antibodiesagainstcarbamylatedproteinsandcycliccitrullinatedpeptidesinsystemiclupuserythematosusresultsfromtwowelldefinedeuropeancohorts |